Abstract
The role of the androgen receptor (AR) as an immunomarker for diagnosis of salivary gland duct carcinoma (SDC) is well known. Other non‐squamous cell head and neck cancers (NSCC‐HN), including a small subset of salivary gland cancers (SGCs), can also express AR. With the increase in effective and powerful new generation of anti‐androgen agents and drugs administered orally, more targetable AR‐driven NSCC‐HN, such as subsets of SGCs, should be investigated for possible expression of AR. In this review, we focus on SGC subtypes, which could express AR and describe the main androgen deprivation therapy (ADT) strategies.
| Original language | English |
|---|---|
| Pages (from-to) | 691-695 |
| Number of pages | 5 |
| Journal | Journal of Oral Pathology & Medicine |
| Volume | 47 |
| Issue number | 7 |
| Early online date | 28 Jun 2018 |
| DOIs | |
| Publication status | Published - 1 Aug 2018 |
Keywords
- abiraterone
- androgen receptor
- enzalutamide
- head and neck
- immunihistochemistry
- non-squamous cell carcinoma
- salivary gland carcinoma
Access to Document
- Androgen_Receptor_in_Salivary_Gland
This is the peer reviewed version of the following article: Yeoh CC, Dabab N, Rigby E, et al. Androgen receptor in salivary gland carcinoma: A review of an old marker as a possible new target. J Oral Pathol Med. 2018; 47: 691–695. , which has been published in final form at https://doi.org/10.1111/j.1600-0714.2018.12741.x.